Couvet, Switzerland – November 14, 2024 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries,…

First operational building dedicated to API development for oligonucleotides, peptides, and complex synthetic conjugates. New facility enhances the Company’s drug substance process R&D capacity to drive innovation across all synthetic modalities and…

We’re excited to announce the latest enhancement to our Early Intermediates manufacturing facility in Changshu, China: a new enzyme fermentation plant that strengthens our biocatalysis capabilities. This expansion increases our total enzyme…

Photo caption (from left to right): Ms. Cindy Koh, Executive Vice President, Singapore Economic Development Board; Dr. Minzhang Chen, Co-CEO, WuXi AppTec; Mr. Heng Swee Keat, Deputy Prime Minister; Dr. Ge Li,…

Exciting moment! We’ve been honored with the 2024 CDMO Leadership Awards in all six core categories: Capabilities, Compatibility, Expertise, Quality, Reliability, and Service, again! Dr. Jinling Chen, our Senior Vice President and Head…

New Capability Spotlight: We just launched a new Blow-Fill-Seal (BFS) aseptic filling line at our drug product site in Wuxi City. Designed for eye drops and inhalants, this BFS line handles volumes…